Guideline for therapy of malignant thyroid tumours: Pleading for an actualization;Leitlinie zur therapie maligner schilddrüsentumoren: Plädoyer für eine aktualisierung

NuklearMedizin

Volumn 43, Issue 4, 2004, Pages 121-123

  Wieler, H ^a   Bartenstein, P ^b   Becker, H P ^a   Bell, E ^c   Decker, P ^d   Jacob, R ^a   Kirsch, C M ^g   Musholt, T ^b   Schwab, R ^a,h   Schwerdtfeger, P ^e   Trampert, L ^f   Kaiser, Klaus P ^a  

^a BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Herz Jesu Krankenhaus Dernbach   (Germany)

^d Krankenanst Mutterhaus der B T

^e Krankenanstalt Mutterhaus der B T

^f Krankenanst Mutterhaus der B T

^g SAARLAND UNIVERSITY   (Germany)

^h RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Guideline; Papillary thyroid carcinoma; T1 tumour

Indexed keywords

IODINE 131;

CANCER SURGERY; CANCER SURVIVAL; GENE EXPRESSION; LYMPH NODE DISSECTION; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; THYROID CARCINOMA; TREATMENT INDICATION; TUMOR CLASSIFICATION; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

EID: 4344671840     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625314     Document Type: Review

References (16)

1. Bal CS, Kumar A, Pant GS. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer. Nucl Med Commun 2003; 24: 203-8.
2. Baudin E, Travagli JP, Ropers J et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998; 83: 553-9.
3. Chow SM, Law SCK, Chan JKC et al Papillary microcarcinoma of the thyroid - prognostic significance of lymph node metastasis and multifocality. Cancer 2003; 98: 31-40.
4. Eichhorn W, Tabler H, Lippold R et al. Prognostic factors determining long term survival in well differentiated thyroid cancer; an analysis of 484 patients undergoing therapy and aftercare at the same institution. Thyroid 2003; 13: 949-58.
5. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumors (WHO International Histological Classification of Tumors, No11). Heidelberg: Springer 1988.
6. Hotze AL, Schumm-Dräger PM. Schilddrüsenkrankheiten - Diagnose und Therapie. 5.Aufl. Berlin: Berliner Medizinische Verlagsanstalt GmbH 2003.
7. Kjellman P, Learoyd DL, Messina M et al. Expression of the RET proto-oncogene in papillary thyroid carcinoma and its correlation with clinical outcome. Br J Surg. 2001; 88: 557-63.
8. LiVolsi VA, Brooks JJ et al. Anaplastic thyroid tumors immunohistology. Am J Clin Pathol 1987; 87: 434.
9. Mann K. Diagnostik und Therapie differenzierter Schilddrü senkarzinome. Internist 2002; 43: 174-85.
10. Moser E, Dietlein M, Dressler J et al. Leitlinie zur Radiojodtherapie (RIP) beim differenzierten Schilddrüsenkarzinom. Nuklearmedizin 1999; 38(6a): 221-2.
11. Musholt TJ, Musholt PB, Khaladj N et al. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 2000; 128: 984-93.
12. Ostwald-Lenz E, Eichler H, Schendera A et al. Gehäuftes Auftreten von Patienten mit anaplastischen Schilddrüsenkarzinomen im Jahre 2002 am Bundeswehrzentralkrankenhaus Koblenz. In: Henning Symposium » Schilddrüse 2003«. 16. Konferenz über die menschliche Schilddrüse. Heidelberg 2004. Berlin: Walter de Gruyter 2004; 209-14.
13. Rodriguez JM, Pinero A, Ortiz S et al. Clinical and histological differences in anaplastic thyroid carcinoma. Eur J Surg 2000; 166: 34-8.
14. Sampson RJ, Oka H, Key Cr et al. Metastases from occult thyroid carcinoma. An autopsy study from Hiroshima and Nagasaki, Japan. Cancer 1970; 25: 803-11.
15. nd Annual Meeting of the Surgical Working Group of Endocrine Surgery (CAEK) of the German Society of Visceral Surgery, 5/6 December 2003, Frankfurt am Main, Germany. Langenbeck's Arch Surg 2003; 388: 427-43.
16. Wittekind C, Meyer JH, Bootz F. TNM Klassifikation maligner Tumoren. 6.Aufl. Berlin: Springer 2003.